Shares of MindWalk Holdings Corp. (NASDAQ:HYFT – Get Free Report) have received an average recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $5.00.
Several analysts have weighed in on the company. Zacks Research raised MindWalk from a “strong sell” rating to a “hold” rating in a report on Monday, September 21st. HC Wainwright restated a “buy” rating on shares of MindWalk in a research report on Monday, July 20th. Weiss Ratings restated a “sell (e+)” rating on shares of MindWalk in a research report on Wednesday, July 15th. Finally, Wall Street Zen raised shares of MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th.
View Our Latest Stock Report on HYFT
Institutional Investors Weigh In On MindWalk
MindWalk Stock Down 6.4%
NASDAQ HYFT opened at $1.40 on Thursday. The stock has a market capitalization of $65.39 million, a P/E ratio of -5.38 and a beta of 0.77. MindWalk has a 52 week low of $0.99 and a 52 week high of $2.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.75 and a current ratio of 1.84. The stock has a fifty day moving average of $1.36 and a 200-day moving average of $1.39.
MindWalk (NASDAQ:HYFT – Get Free Report) last issued its quarterly earnings results on Monday, September 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04). The firm had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.25 million. MindWalk had a negative net margin of 105.11% and a negative return on equity of 133.26%. On average, equities research analysts forecast that MindWalk will post -0.28 EPS for the current year.
About MindWalk
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.
Featured Stories
- Five stocks we like better than MindWalk
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for MindWalk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MindWalk and related companies with MarketBeat.com's FREE daily email newsletter.
